Instil Bio, Inc. (TIL)
TIL moved a median of -0.10% 30 minutes after news, and -0.39% by the close. How TIL actually reacts to news — the realized, point-in-time move the market made, measured across 180 labeled events over the last three years with zero look-ahead.
TIL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 148 |
| 30-min | -0.10% | 45% | 168 |
| 60-min | -0.27% | 45% | 179 |
| to close | -0.39% | 42% | 177 |
| Middle 50% of TIL reactions | -1.69% to +1.43% |
|---|---|
| Median reaction (30-min) | -0.10% |
| Measured reactions | 180 |
Half of all Instil Bio, Inc. news events land between -1.69% and +1.43% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TIL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TIL's baseline. Nothing else.
Recent TIL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q Instil Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.10% | |
| Form 8-K Instil Bio, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.10% | |
| Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +1.10% | |
| Form 8-K Instil Bio, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 10-Q Instil Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.86% | |
| Form 8-K Instil Bio, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.86% | |
| Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -0.86% | |
| Form ARS Instil Bio, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -5.69% | +0.62% | |
| Form DEF 14A Instil Bio, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -5.69% | +0.62% | |
| Form DEFA14A Instil Bio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -5.69% | +0.62% | |
| Form 8-K Instil Bio, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.82% | |
| Form 10-K Instil Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.27% | -6.82% | |
| Form 8-K Instil Bio, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | -6.82% | |
| Form S-8 Instil Bio, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.27% | -6.82% | |
| Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.27% | -6.82% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.18% | -0.39% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Instil Bio, Inc. (TIL) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.63% | -1.40% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Instil Bio, Inc. (TIL) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.69% | -2.35% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Instil Bio, Inc. (TIL) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | -0.31% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.64% | +1.14% | |
| Instil Bio, Inc. (TIL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | -0.78% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.35% | +1.63% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Instil Bio, Inc. (TIL) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.70% | +1.27% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Instil Bio, Inc. (TIL) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | — | +1.71% | |
| Instil Bio, Inc. (TIL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.64% | +0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Instil Bio, Inc. (TIL) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +0.71% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.70% | +3.07% | |
| Form 8-K Instil Bio, Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +4.63% | +7.32% | |
| Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco | Press release | GlobeNewswire | +6.11% | +9.90% | |
| Form 10-Q Instil Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.03% | — | |
| Form 8-K Instil Bio, Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | — | |
| Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.03% | — | |
| Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) | Press release | GlobeNewswire | +0.10% | -11.62% | |
| Form 10-Q Instil Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.33% | +1.20% | |
| Form 8-K Instil Bio, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | +1.20% | |
| Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.33% | +1.20% | |
| Form 8-K Instil Bio, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -5.92% | |
| ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China | Press release | GlobeNewswire | +1.78% | -12.57% | |
| Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors | Press release | GlobeNewswire | +0.83% | +1.10% | |
| Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program | Press release | GlobeNewswire | -1.95% | -2.51% | |
| Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer | Press release | GlobeNewswire | +4.76% | -15.31% | |
| Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -14.74% | -5.41% | |
| Form 8-K Instil Bio, Inc. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +4.45% | +1.61% | |
| Form 8-K Instil Bio, Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -5.23% | +10.22% | |
| Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago | Press release | GlobeNewswire | +1.70% | -12.05% | |
| Form 8-K Instil Bio, Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +2.42% | +33.75% | |
| Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated i | Press release | GlobeNewswire | +2.42% | +33.75% | |
| Form 10-Q Instil Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.09% | -7.08% | |
| Form 8-K Instil Bio, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -1.09% | -7.08% | |
| Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.09% | -7.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TIL section they belong to.
Where else TIL is measured.
TIL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Instil Bio, Inc.'s median reaction calculated?
Every labeled TIL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 180 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of TIL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TIL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.